The 2016 ASCP Annual Meeting took place in Scottsdale, AZ from May 30 - June 3, 2016. The meeting included representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry that discussed key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Steering Committee chaired by Drs. Husseini Manji and Michael Thase with representation of the sectors that are part of the ASCP community led the direction of the meeting. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, the pharmaceutical industry and academia comprise the 2016 Steering Committee. A Program Committee under the leadership of Drs. Holly Swartz and Alan Gelenberg were responsible for review of all program submissions.

Thank you to all who attended the 2016 ASCP Annual Meeting, May 30 - June 3, 2016 in Scottsdale, AZ!